(Q37602383)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

review article

1 reference

title

Current status of anti-angiogenic agents in the treatment of ovarian carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

main subject

angiogenesis inhibitor

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Alfonso Sánchez-Muñoz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

César Mendiola Fernández

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Emilio Alba Conejo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Antonio González-Martín

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

589-595

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-009-0409-8

8 February 2020

exact match

0 references

cites work

Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis

1 reference

12 December 2020

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

12 December 2020

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

1 reference

12 December 2020

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

Angiogenesis and metastasis

1 reference

12 December 2020

Angiogenesis in epithelian ovarian cancer

1 reference

12 December 2020

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

12 December 2020

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

1 reference

12 December 2020

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

12 December 2020

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

12 December 2020

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

1 reference

12 December 2020

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

1 reference

12 December 2020

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

12 December 2020

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

1 reference

12 December 2020

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

1 reference

12 December 2020

10.1007/S12094-009-0409-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference